Takeaway

• Vilobelimab leads to a 23.9% relative reduction in 28-day all-cause mortality compared with placebo.

Severe COVID-19 manifests in widespread complement activation in the lungs and kidneys, with increased levels of C5a and C5b. C5a, a potent anaphylatoxin, activates the coagulation system and may contribute to the development of acute...